When developing interventions to improve population health, particularly among minority groups, research must take a culturally sensitive approach that is targeted to the specific needs of that population, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities. He also emphasized the importance of clinicians’ role in population health.
When developing interventions to improve population health, particularly among minority groups, research must take a culturally sensitive approach that is targeted to the specific needs of that population, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities. He also emphasized the importance of clinicians’ role in population health.
Transcript (slightly modified)
What are some important considerations in designing health interventions for minority populations?
The 2 parts are, first of all, the attitude. I believe our attitude determines our altitude, how far we can go and how high we can go. It’s the recognition that all racial/ethnic minorities are different, all populations are different, and the first attitude must be that of humility, of really trying to understand the cultural aspects, the behavioral aspects, the determinants of population health.
Secondly, it’s some sort of ascertainment: compiling and knowing the epidemiology, the risk factors, the rates, which cancers and risk factors are the most prominent and what can be done about it. Then, to the extent possible, to design interventions that are culturally competent, meaning with the population, not on the population. That might mean training bilingual, bicultural individuals who can reach out to the community.
I think that conducting this, sustaining that, is the way to go. We’ve been able to show that it has worked. It’s more effective than, shall we say, just a missile approach or whatever.
What role can clinicians play in improving population health?
I want to reinforce how important, and never to underestimate, the provider’s influence on healthcare of the patient. The provider is the major gateway, decision maker, and trusted individual to do this, and so that’s a tremendous responsibility and obligation to do. I feel really privileged whenever I can to just reflect the research and the patient community on how important the provider’s role is.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More